samedan logo
 
 
 
spacer
home > pmps > winter 2002 > modified-release oral solid dosage forms - part i: coating and matrix formation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Modified-Release Oral Solid Dosage Forms - Part I: Coating and Matrix Formation

This article provides a comprehensive review of the basics of matrix and coating systems on which new drug delivery companies have based their products. It focuses on the investigation of the underlying technical principles of oral solid dosage forms (tablets and particles) by classifying them as matrix or coating systems. The materials chemistry and processing (formulation and formation methods) of matrix or coating oral solid dosage forms have been investigated. Processing of commercial matrix or coating systems is different.

The conventional processing described provides the basics for what is now all-in-one granulation using fluid beds (top-spray for matrices and bottom or tangential-spray for coatings). Each system's specific parameters (polymer hydration and gel formation for matrices, insolubility for coatings) and common parameters (particle size, shape of all particles, drug per cent, polymer blend solubility, flexibility and compressibility) are discussed. The current trends resulted from these basic technical formation principles.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Emmanuel Dimotakis PhD and Robert A Nash PhD, Department of Chemical
and Pharmaceutical Engineering at the New Jersey Institute of Technology

Dr Emmanuel Dimotakis joined Sun Chemical as an Associate Scientist in 1998 and is currently a Scientist II. His expertise is in product development with emphasis on nanostructure-property relationships and formulation/rheology of polymers for coatings/colorants, nanomaterials and lithography. He has introduced products into the market, published 15 articles, 3 US/WO Patents (others are pending) and 12 government reports to NASA/DOD.

He was formerly with E. Merck and before that with MER Corporation. Dr Dimotakis received his PhD in Chemistry at Michigan State University in 1990 and undertook Postdoctoral work in Materials Science and Engineering at the University of Illinois at Urbana-Champaign.

Dr Robert A Nash is Adjunct Professor of Pharmaceutical Engineering at Stevens Institute of Technology in Hoboken, USA. Before that he taught at NJIT and St John's University.

Dr Nash spent 24 years in the US pharmaceutical industry with Merck, Lederle and the Purdue Frederick Co. in roles varying from Researcher to Manager of Pharmaceutical R&D. Dr Nash is Co-Editor of Pharmaceutical Process Validation published by Marcel Dekker & Co, New York. He is also a Consultant to the US FDA on validation and GMP matters.


spacer
Dr Emmanuel Dimotakis
spacer
spacer
spacer
Dr Robert A Nash
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UKs Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement